Molecular characterization and targeted therapeutic approaches in breast cancer

Angela Toss and Massimo Cristofanilli

Abstract

Despite the wide improvements in breast cancer (BC) detection and adjuvant treatment, BC is still responsible for approximately 40,000 deaths annually in the United States. Novel biomarkers are fundamental to assist clinicians in BC detection, risk stratification, disease subtyping, prediction of treatment response, and surveillance, allowing a more tailored approach to therapy in both primary and metastatic settings. In primary BC, the development of molecular profiling techniques has added prognostic and predictive information to conventional biomarkers - estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Moreover, the application of next-generation sequencing and reverse-phase protein microarray methods in the metastatic setting holds the promise to further advance toward a personalized management of cancer. The improvement in our understanding on BC biology associated with the study of the genomic aberrations characterizing the most common molecular subtypes allows us to explore new targets for drug development. Finally, the integration of cancer stem cell-targeted therapies and immune therapies in future combination regimens increases our chances to successfully treat a larger proportion of women with more aggressive and resistant metastatic disease. This article reviews the current state of novel biological markers for BC, the evidence to demonstrate their clinical validity and utility, and the implication for therapeutic targeting.

Introduction

Breast cancer (BC) represents the most common cancer among women; there were 232,670 estimated new cases and 40,000 estimated deaths in the United States in 2014 [1]. In recent decades, the widespread use of mammographic screening has increased the rate of regional disease detection, and the development of more effective adjuvant chemotherapeutic regimens, extended use of endocrine therapies, and standard application of targeted agents have all contributed to improve outcomes of women with primary BC. However, the widespread application of these diagnostic and therapeutic interventions requires significant resources and is associated with treatment-related morbidity; therefore, determining the subgroup of patients who can truly benefit from the implementation of such advanced measures is still a challenge.

For years, researchers have investigated clinical tools and molecular approaches with the aim of discovering a combination of clinical and biological features that could predict cancer features and behavior, allowing a more tailored approach to therapy. New biomarker development is fundamental to assist clinicians in BC detection and diagnosis, risk stratification, disease subtyping, prediction of treatment response, and surveillance, allowing a personalized cancer management. The integration between novel biomarkers and routinely tested clinicopathological features, such as hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status, may guide clinicians in systemic therapy decisions in both primary and metastatic settings. This article reviews the current state of novel biological markers for BC, the evidence to demonstrate their clinical validity and utility, and the implication for therapeutic targeting.

Breast cancer subtypes and gene expression profile tests

From the clinical point of view, BC can be classified according to the immunohistochemistry/fluorescence in situ hybridization (IHC/FISH) profile and divided on the basis of the presence of estrogen receptor (ER), progesterone receptor (PR), and HER2.

At the molecular level, Perou and colleagues [2] analyzed BC gene expression patterns derived from cDNA
microarrays, initially identifying four major intrinsic gene signatures: luminal, HER2-enriched, basal-like, and normal breast-like subtype. Subsequent studies led to the division of luminal tumors in two subgroups (luminal A and luminal B) and demonstrated a correlation between these gene expression patterns and survival, disease relapse, site of metastasis, and chemotherapy response [3-5]. Over the years, other molecular subtypes have been described, such as claudin low and molecular apocrine tumors. In 2009, Parker and colleagues [6] developed an efficient 50-gene classifier, called Prediction Analysis of Microarray (PAM50), that reanalyzed the previous five subgroups defining the four major intrinsic subtypes currently known: luminal A, luminal B, HER2-enriched, and basal-like (Table 1).

In recent years, five novel gene expression prognostic tests for BC have been developed: MammaPrint, MapQuant Dx, Oncotype DX, PAM50, and Theros Breast Cancer Index. The rationale for developing multi-gene-based prognostic tests is not only to add prognostic and predictive information to conventional biomarkers but to provide more reliable and reproducible techniques than the IHC-based assays, reducing technical errors and subjective interpretation [7]. One of the first commercially available and US Food and Drug Administration (FDA)-approved signatures was the 70-gene MammaPrint assay, which stratifies patients into low- or high-risk for distant metastases at 5 years. More recently, the 21-gene Oncotype DX assay was developed to estimate the risk of relapse in ER+, node-negative BC and their chemosensitivity. Oncotype DX divides patients into three groups on the basis of their recurrence score (RS): low-risk (RS of less than 18), intermediate-risk (RS of 18 to 30), or high-risk (RS of more than 31) [8]. As previously described, the PAM50 test defined the four major intrinsic subtypes of BC through the analysis of 50 classifier genes and five control genes. Along with the identification of subtypes, PAM50 has been shown to be an independent predictor of survival in BC [9]. PAM50 generates a numerical score (risk of recurrence, or ROR) that along with clinical features estimates the risk of relapse at 10 years in postmenopausal women with stage I/II node-negative or stage II node-positive (one to three positive lymph nodes) and HR-positive BC [10].

In patients with ER-positive and node-negative early BC, the PAM50 platform has been demonstrated to provide more prognostic information than the Oncotype DX test, since PAM50 was better able to distinguish between intermediate- and high-risk patients [11]. On these bases, the platform was recently cleared by the FDA. Notably, in the same study, PAM50 and Oncotype DX assays were compared with the IHC4 score. IHC4 is a prognostic model that combines quantitative IHC measures of ER, PR, HER2, and Ki-67 performed in high-quality laboratories. In this study, relatively similar information was provided by ROR and IHC4 in all patients, but in the HER2-negative/node-negative subgroup, ROR was more informative than IHC4 [11].

The other multi-gene-based assays showed similar prognostic performances, and their prognostic value is due mainly to the ability of providing a robust measurement of proliferation activity, particularly in ER+/HER2- patients [12]. However, only the Oncotype Dx assay achieved level IB evidence and has been incorporated into current National Comprehensive Cancer Network and American Society of Clinical Oncology guidelines, since it demonstrated a role as a predictive test in two prospectively designed retrospective studies with tumor specimens obtained from randomized clinical trials comparing tamoxifen with or without chemotherapy [13]. The evaluation and the comparison between the predictive value of PAM50 and Oncotype DX are ongoing in the prospective RxPONDER trial (NCT01272037), and results from the prospective MINDACT (NCT00433589)

| Intrinsic subtype | cDNA microarrays | IHC | Treatment |
|-------------------|-----------------|-----|-----------|
| Luminal A         | The highest expression of the ER α gene, GATA-binding protein 3, X-box-binding protein 1, trefoil factor 3, hepatocyte nuclear factor 3 α, and estrogen-regulated LVI-1 | ER- and/or PR-positive HER2-negative Ki-67 < 14% | Endocrine therapy (chemotherapy for selected patients) |
| Luminal B         | Low to moderate expression of the luminal-specific genes, including the ER cluster | ER- and/or PR-positive HER2-negative with Ki-67 ≥14% | Endocrine therapy ± chemotherapy |
|                   |                  | ER- and/or PR-positive HER2-positive with any Ki-67 | Chemotherapy + anti-HER2 therapy + endocrine therapy |
| HER2-enriched      | High expression of several genes in the ERBB2 amplicon at 17q22.24, including ERBB2 and GRB7 | ER- and PR-negative HER2-positive | Chemotherapy + anti-HER2 therapy |
| Basal-like        | High expression of keratins 5 and 17, laminin, and fatty acid-binding protein 7 | ER- and PR-negative HER2-negative | Chemotherapy |

ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; PR, progesterone receptor.
and TAILORx (NCT00310180) trials are awaited to have direct evidence of the predictive value in the adjuvant setting of, respectively, MammaPrint and Oncotype DX assays.

Through multi-gene profiling tools, more information can be obtained from tumor tissues. For instance, the PAM50 platform provides quantitative values for proliferation, luminal gene expression, estrogen receptor 1 (ESR1), progesterone receptor gene (PGR), and HER2. Moreover, on the same tissue used for MammaPrint, the BluePrint test can be performed. BluePrint is a molecular subtyping assay that analyzes the mRNA levels of 80 additional genes to better discriminate among the molecular subtypes. Combining MammaPrint and BluePrint allows patients to be stratified into luminal-type/ MammaPrint low-risk (similar to luminal A), luminal-type/ MammaPrint high-risk (similar to luminal B), HER2-type, and basal-type [14]. This stratification has demonstrated several implications in neoadjuvant trials. The recent CTNeoBC pooled analysis of 12 neoadjuvant randomized trials highlighted that patients who achieve a pathologic complete response (pCR) show more favorable outcomes. Notably, the achievement of pCR varied according to BC subtype, and the prognostic value was greatest in more aggressive subtypes. In particular, the association between pCR and long-term outcomes was strongest in patients with HR+/HER2-/grade 3 tumors, triple negative breast cancer (TNBC), and HR+/HER2+ who received trastuzumab [15]. Interestingly, Glück and colleagues [16] investigated the correlation between pCR rate after neoadjuvant chemotherapy (NACT) and long-term outcome comparing BluePrint and MammaPrint combined model versus clinical subtyping using IHC/FISH. This study confirmed the notable benefit in response to neoadjuvant treatment, and thus in the long-term outcome, of patients with HER2-type and basal-type. Overall, BluePrint with MammaPrint molecular subtyping was shown to improve the stratification of patients in the neoadjuvant setting, improving prognostic estimation versus IHC/FISH [16]. Thus, molecular signatures provide a more accurate representation of BC biological features, allowing prognostication at the time of initial diagnosis, prediction of benefit from adjuvant therapy, and response to NACT (Table 2). Nevertheless, despite their demonstrated efficacy, there are still large geographic differences in the adoption of these tests, probably reflecting variations in economies, health systems, and physician training. Therefore, in many institutions, clinical and immunohistochemical evaluation remains the reference method for the classification of BC.

**Genomic aberrations in breast carcinogenesis as therapeutic targets**

**Luminal subtypes and the PI3K/akt/mTOR pathway**

Luminal subtypes are characterized by the expression of ER and represent a heterogeneous category in terms of gene expression and clinical outcomes. The principal characteristic of this group is the luminal expression signature, composed of ESR1, GATA3, FOXA1, XBP1, and cMYB. The most frequent mutations in the luminal A subtype are PIK3CA (45%), MAP3K1 and GATA3 (13% each), TP53 (12%), and CDH1 (9%). The most frequent mutations in luminal B tumors are TP53 and PIK3CA (29% each), GATA3 (13%), and TTN (12%) gene mutations (Table 3) [17,18]. In addition to TP53 mutations, frequently within luminal B subtypes, several other

---

**Table 2 Main features of the principal available multi-gene assays in breast cancer**

| Assay       | Number of genes | MammaPrint | Oncotype DX | PAM50 |
|-------------|-----------------|------------|-------------|-------|
| Sample     | 70              | Formalin-fixed, paraffin-embedded tissue, or fresh-frozen tissue | Formalin-fixed, paraffin-embedded tissue, or fresh-frozen tissue | 50 + 5 control genes |
| Technique  | DNA microarray  | Quantitative PCR | Quantitative PCR and nCounter technology |
| Study population | Patients <61 years, with T1-T2, N0 disease (largely ER-positive) | Patients with ER-positive, node-negative disease | Patients with stage I to III breast cancer |
| Output     | Low- or high-risk patients | Recurrence score: low, intermediate, or high | Risk of recurrence: low, medium, or high |
| Guidelines | FDA-approved    | National Comprehensive Cancer Network, American Society of Clinical Oncology | FDA-cleared |

Clinical applications:
- Accurate and reproducible representation of BC biological features [7]. Overall risk assessment of BC recurrence [8]. BluePrint and MammaPrint improve stratification of patients in the neoadjuvant setting [14,16].
- Accurate and reproducible representation of BC biological features [7]. Overall risk assessment of BC recurrence [8]. Prognostic role in tamoxifen-treated patients with positive nodes [13]. Prediction of CMF efficacy in ER-positive, node-negative BC patients [13]. Prediction of FAC efficacy in ER-positive, node-positive BC patients [7].
- Accurate and reproducible representation of BC biological features [7]. Categorization of tumors into the four intrinsic subtypes [8,9]. Prediction of DFS and OS [9]. Estimate of the risk of relapse at 5 to 15 years in ER-positive, node-positive and -negative BC patients [10]. Prediction of benefit of tamoxifen in pre-menopausal patients [9].

---

BC, breast cancer; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; DFS, disease-free survival; ER, estrogen receptor; FAC, fluorouracil, doxorubicin, and cyclophosphamide; FDA, US Food and Drug Administration; OS, overall survival; PAM50, Prediction Analysis of Microarray; PCR, polymerase chain reaction.
Table 3 The most frequently mutated genes in each molecular subtype [17,18]

| Molecular Subtype | Luminal A | Luminal B | HER2-enriched | Basal-like |
|-------------------|-----------|-----------|-------------|-----------|
| PIK3CA            | 45%       | 29%       | 72%         | 80%       |
| MAP3K1            | 13%       | 29%       | 39%         | 19%       |
| GATA3             | 13%       | 13%       | 14%         | 11%       |
| TP53              | 12%       | 12%       | 8%          | 7%        |
| CDH1              | 9%        | 7%        | 8%          | 7%        |
| TTN               | 9%        | 5%        | 8%          | 7%        |
| MLL3              | 7%        | 5%        | 8%          | 7%        |
| MAP2K4            | 6%        | 5%        | 8%          | 5%        |
| NCO1              | 5%        | 5%        | 7%          | 5%        |
| PTK1              | 4%        | 4%        | 7%          | 5%        |
| PTEN              | 4%        | 4%        | 7%          | 5%        |

HER2, human epidermal growth factor receptor 2.

mechanisms of resistance to endocrine therapies include the dysregulation of normal cell cycle control. In particular, cyclin D1 and cyclin-dependent kinase (CDK) 4/6 cooperate to phosphorylate and inactivate the retinoblastoma tumor-suppressor protein (RB), allowing cell cycle progression even in BC cells with efficient inhibition of ER [22]. Recently, the final results of the phase II PALOMA-1 trial (NCT00721409) reported a statistically significant improvement in progression-free survival (PFS) with the addition of a specific inhibitor of CDK 4/6 activity (palbociclib) to letrozole compared with letrozole alone (20.2 versus 10.2 months). The overall survival (OS) analysis showed a trend in favor of combined treatment but was not statistically significant [23]. On these bases, palbociclib and other CDK 4/6 inhibitors, including LEE011 and abemaciclib, are currently under investigation in several phase III clinical trials.

Genetic mutations and major structural defects in the DNA strands may permanently compromise gene function. In contrast, epigenetic aberrations can keep the gene structure intact and can be partially or completely reverted, restoring the original gene conformation. These transient modifications are dynamically established by enzymes which respond to intrinsic and extrinsic stimuli, and include methylation, histone acetylation, phosphorylation, ubiquitination, citrullination, sumoylation, and ADP ribosylation. In the last decade, several therapies targeting epigenetic modifying enzymes have been developed, and the FDA has approved azacitidine and decitabine for high-risk myelodysplastic syndrome and two histone deacetylase (HDAC) inhibitors (vorinostat and romidepsin) for cutaneous T-cell lymphoma [24]. For what concerns BC, recent research highlighted that DNA methylation may influence the tumor receptor status. In particular, ER positivity is linked to the methylation of specific genes, including RASSF1A, CCND2, GSTP1, and TWIST. Vesuna and colleagues [25] reported that TWIST, a gene overexpressed in high-grade BC, promotes downregulation of ER through the recruitment of DNMT3B. On this basis, azacitidine and valproic acid (HDAC inhibitor) have been investigated in this setting and showed the capability of partially restoring ER expression [25]. Moreover, in the ENCORE 301 study (NCT00676663) [26], entinostat was shown to restore sensitivity to hormonal therapy and to improve PFS and OS when given in combination with exemestane in patients with ER-positive advanced BC resistant to previous aromatase inhibitors. On the basis of this phase II trial, entinostat received a Breakthrough Therapy designation from the FDA and was included in the phase III E2112 trial (NCT02115282) that started at the beginning of 2014.
HER2-positive breast cancer

DNA amplification of HER2 gene is considered the main mechanism of HER2 protein overexpression in HER2-positive tumors. This subtype of tumors represents 20% to 25% of all BC, shows HER2 protein overexpression by IHC/FISH, and has been associated with poor disease-free survival rates and increased chemo-resistance. Within this clinically defined group, at least two different molecular subtypes have been identified. About 50% of clinically HER2-positive tumors express the HER2-enriched mRNA subtype, whereas the rest express predominantly the luminal mRNA subtype. HER2-enriched tumors show significantly higher expression of several receptor tyrosine kinases, including FGFR4, epidermal growth factor receptor (EGFR), HER2 itself (80%), and genes within the HER2 amplicon (that is, GRB7). On the other hand, the luminal mRNA subtypes show higher expression of the luminal signature, including GATA3, BCL2, and ESR1. In HER2-enriched tumors, the main somatic mutations were TP53 mutations (72%) and PIK3CA mutations (39%), whereas GATA3 mutations were observed only in luminal subtypes [17,20].

The HER family consists of four human EGFRs. Each member of the HER family has identified ligands, with the exception of HER2. Ligand binding to extracellular domains promotes homo- or hetero-dimerization of these receptors and promotes their intrinsic tyrosine kinase activity. In this way, the dimerization triggers...
various intracellular signaling pathways, including the PI3K/AKT/mTOR, RAS/RAF/MEK/MAPK, and STAT pathways. The development of trastuzumab has significantly improved the prognosis of patients with HER2-positive BC, but unfortunately a number of patients still develop resistance and progressive disease. Several mechanisms of resistance to trastuzumab have been identified: impaired access to HER2 by expression of extracellular domain-truncated HER2 (p95 HER2) or overexpression of MUC4; alternative signaling from IGF-1R, other HER family members, or MET; loss of downstream controllers (PTEN and p27); and activation of downstream signaling pathways (PI3K-Akt, MEK, MAPK, and mTOR) [27].

In the last few years, several therapeutic strategies for overcoming trastuzumab resistance have been developed, including lapatinib, pertuzumab, and trastuzumab-DM1 (Table 4). These agents act by different mechanisms on the HER2 protein and, in pre-clinical and clinical models, have been shown to be effective even in trastuzumab-resistant cells [28]. Future research should be directed to identify biomarkers that could help to choose which HER2-targeted therapy should be preferred. For instance, lapatinib is a dual HER1 (EGFR) and HER2 tyrosine kinase inhibitor and acts on the intracellular ATP-binding site of the kinase domain of the receptor. Additional studies are needed to clarify whether tumor cells with extracellular domain-truncated HER2 or with alternative signaling from EGFR could benefit from the mechanism of action of lapatinib. In these cases, reverse-phase protein microarray (RPPA) and next-generation sequencing (NGS) tests could be used as clinical diagnostic assays to study HER2 protein status or alterations within the signaling pathways, guiding treatment decision-making. Moreover, in a subanalysis of the EMILIA trial (NCT00829166) [29], HER2 mRNA analysis by quantitative reverse transcriptase-polymerase chain reaction and the PIK3CA mutational status were analyzed on tumor tissues. Cases expressing higher levels of HER2 mRNA showed better OS from T-DM1, whereas PIK3CA mutational status was not demonstrated to predict outcomes in patients receiving T-DM1. On the other hand, in the group receiving lapatinib and capecitabine, HER2 mRNA was not demonstrated to influence outcomes, whereas patients with mutated PIK3CA status showed shorter median PFS and OS [30]. In conclusion, future research is necessary to investigate BC cells at the molecular level in order to select genomic and proteomic tools that could guide targeted treatment choices.

Other potential strategies for overcoming trastuzumab resistance include PI3K/AKT/mTOR pathway inhibitors, HER2 vaccines, inhibitors of alternative signaling molecules (IGF-1R and MET), eratumoxomab, and defucosylated trastuzumab. Moreover, dual inhibition of HER2, combining more monoclonal antibodies against the HER2 extracellular domain, could be another effective approach to treat trastuzumab-refractory HER2-positive tumors.

In the last few years, the inhibition of heat shock protein 90 (Hsp90) has emerged as an attractive approach in order to overcome trastuzumab resistance. Hsp90 is a ubiquitous molecular chaperone fundamental for correct folding and maturation of numerous cellular proteins. Inhibition of the Hsp90 chaperone cycle leads to protein ubiquitination and subsequent degradation by the proteasome. Because Hsp90 client proteins are frequently products of oncogenes, Hsp90 may represent an important target in cancer therapy. Moreover, because Hsp90 protects cells from stress-induced damage, Hsp90 inhibitors could sensitize cells to cytotoxic agents and

Table 4 Biologic anti-HER2 agents approved for breast cancer treatment

| Agent      | Approval | Mechanism of action                                                                 | Indications                                                                 |
|------------|----------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Trastuzumab| 1998     | Humanized monoclonal antibody against the extracellular domain of HER2. It triggers HER2 internalization and degradation. | Adjuvant BC (from the first line)                                           |
| Lapatinib  | 2006     | Dual inhibitor of the intracellular tyrosine kinase domains of both HER1 (EGFR) and HER2. | Metastatic BC (after prior anthracycline, taxane, and trastuzumab)          |
| Pertuzumab | 2012     | Humanized monoclonal antibody against the extracellular dimerization domain of HER2. It blocks the heterodimerization of HER2 with other HER family. | Neoadjuvant BC (with trastuzumab and docetaxel in locally advanced, inflammatory, or early stage BC -either >2 cm or node-positive) |
| T-DM1      | 2013     | Trastuzumab-like activity. Targeted intracellular delivery of cytotoxic emtansine.     | Metastatic BC (after the first line or in first line if trastuzumab-resistance) |

BC, breast cancer; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2.
radiation therapy. Hsp90 inhibitors are currently under investigation in several clinical trials and have shown early promising results in defined molecular subgroups of solid tumors such as the HER2-positive BC [31]. HER2 is one of the most sensitive client proteins to Hsp90 inhibition and thus in the absence of Hsp90 activity HER2 is subject to proteolysis, and drugs that target HER2 can be more effective. To date, promising results in terms of objective tumor response have been observed with tanezumycin in combination with trastuzumab in patients progressing on trastuzumab (NCT00773344) [32] and more recently with single-agent ganetespib in trastuzumab-refractory HER2-positive tumors and TNBC (NCT01677455) [33].

**Subtypes of triple-negative breast cancer and p53 mutations**

TNBC constitutes about 15% to 20% of all BC and is clinically defined by the absence of ER and PR positivity and the lack of HER2 overexpression by IHC. This heterogeneous group of tumors is more aggressive, with higher rates of relapse and worse OS. The basal-like tumor represents a specific group characterized by the expression of genes found in normal basal/myoepithelial breast cells, including high-molecular-weight basal cytokeratins (CK5/6, CK14, and CK17) or EGFR or both. For years, the relationship between TNBC and basal-like tumors has been controversial. However, not all TNBCs are identified as basal-like tumors by gene expression, and not all basal-like tumors are clinically TNBC; therefore, these two terms may not be considered synonymous. In 2011, Lehmann and colleagues [34] identified six different subtypes within TNBC by performing RNA microarray analyses: two basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) subtype. BL1 and BL2 subtypes heavily express cell cycle and DNA damage response genes (ATR/BRCA), and representative cell lines respond particularly to anti-mitotic and DNA-damaging agents, such as platinum agents. In particular, the poly (ADP-ribose) polymerase (PARP) family of enzymes, the DNA damage response kinase ATR and its effector kinases CHEK1/2, and the regulator of the G1 checkpoint WEEl kinase represent attractive pharmacological targets for radiosensitization and chemosensitization in these cells. Several ATR, CHEK1/2, and WEE1 inhibitors are currently under evaluation in phase I/II trials in TNBC, and a number of PARP inhibitors are already included in phase III studies. On the other hand, the IM subtype is highly enriched in immune cell signaling, but it is still unclear whether this genetic profile is reflective of cancer cells or stromal immune infiltrate. M and MSL subtypes express genes involved in epithelial-mesenchymal transition (EMT), motility, and cell differentiation pathways, and its representative cell lines respond to PI3K/mTOR inhibitors and dasatinib. Moreover, the MSL subtype is enriched for mesenchymal stem cell–associated genes. Finally, the LAR subtype expresses luminal signature and androgen receptor (AR) signaling. LAR subtypes are associated with better OS, and a recent phase II trial of bicatulamide in AR-positive TNBC (NCT00468715) reported a 6-month clinical benefit rate of 19% with a median PFS of 12 weeks, showing proof of principle for the effectiveness of minimally toxic androgen blockade in this subgroup of patients [35]. Currently, enzalutamide and abiraterone are also under evaluation in phase II studies in this select subset of patients.

Previous evaluations of gene expression profiles in TNBC had led to the identification of another subgroup named claudin-low and characterized by the absent expression of luminal differentiation markers, high enrichment for EMT markers, immune response genes, and cancer stem cell (CSC)-like features [36]. However, Lehmann and Pietenpol [37] observed that most of the tumors classified as claudin-low are composed of M and MSL subtypes, and concluded that the classification into basal-like and non-basal-like subtypes oversimplifies the molecular heterogeneity of TNBC. A comprehensive classification of TNBC in molecular subtypes has the potential to guide treatment decision-making and future clinical trials investigating targeted therapies.

TP53 mutations are the most frequent clonal aberrations in basal-like tumors (80%), but the loss of TP53 function, through gene mutations or dysfunctions in the TP53 pathway, occurs within almost all basal-like tumors. TP53 is a tumor-suppressor gene that, after the activation by oncogenic stress signals, promotes either cell cycle arrest and DNA repair or cell apoptosis. The activity of TP53 is achieved by downstream targets (p21), indirect targets (PTEN), cell cycle regulation proteins (Chk1 and Chk2), and DNA repair proteins (PARP-1 and BRCA-1). Moreover, the TP53 pathway is influenced by prolyl isomerase 1, which is responsible for post-translational modifications and histone acetylation, which applies epigenetic modifications to the TP53 gene. Mutated TP53 represents a potential target for TNBC treatment but this approach remains a challenge on several fronts since our knowledge of the TP53 pathway is still largely incomplete and the heterogeneity of TNBC comprises different behavior even among the subgroups showing aberrant TP53 function [38]. In addition to loss of TP53, loss of RB1 and BRCA1 functions are common basal-like features. PIK3CA is the next most commonly mutated gene (9%). However, interferences in PI3K pathway activity are even more frequent in basal-like tumors and include loss of PTEN and INPP4B. Furthermore, in basal-like cancers, many of the elements of the PI3K/AKT/mTOR and RAS/RAF/MEK/MAPK pathways were
amplified, including PIK3CA (49%), KRAS (32%), BRAF (30%), and EGFR (23%) [17].

To date, on these molecular bases, many agents have been included in clinical trials for patients with TNBC. In particular, cabozantinib, a MET-, VEGFR2-, and RET-targeted tyrosine kinase inhibitor, is under evaluation in a phase II trial (NCT01738438). OTX015 and TEN-010 are bromodomain and extra-terminal domain (BET) bromodomain inhibitors that can inactivate the expression of oncogenes such as Myc. These novel epigenetic modulators of gene expression are included in phase I trials for patients with TNBC and solid tumors.

**Breast cancer heterogeneity**

BC represents a heterogeneous disease at the population and single-cell level. Cancer cells within the same tumor can exhibit different genotypes as well as phenotypes. In the last decade, the development of NGS methods provided fundamental insight into the genetic intra-tumor heterogeneity, and different models have been proposed to explain the origins of this phenomenon. The first model, proposed by Nowell in 1976, suggests that tumor masses are caused by the expansion of one (monoclonal) or multiple (polyclonal) cellular clones [39]. In the CSC model, some precursor cells give rise to a different subpopulation of cells within the tumor with a hierarchical arrangement. Lastly, in the mutator hypothesis, tumor mass develops because of the gradual and random accumulation of genetic mutations, causing a wide range of diversity [40].

In the last few years, a plastic CSC model has been developed. The emerging CSC model suggests that cancer initialization, progression, and metastasization are driven by a specific subpopulation of tumor cells (named CSCs) that express two fundamental characteristics: the capacity for self-renewal and the ability to efficiently reconstitute differentiated tumors. These cells are associated with phenotypic plasticity with the acquisition of peculiar mesenchymal characteristics during specific phases of the metastatic process. The EMT is a latent embryonic process that, when aberrantly activated in cancer cells, promotes the reprogramming of epithelial cancer cell toward a mesenchymal motile phenotype with migratory and invasive capacities and thus metastatic potential [41]. EMT is a highly dynamic process that is represented by several steps and multiple intermediate states and that contributes to increase the cancer heterogeneity and plasticity. The transition is induced by several extracellular stimuli, including different growth factors (EGF, PDGF, and TGFβ), Hedgehog (Hh), Wnt/β-catenin, Notch, and components of the extracellular matrix and cellular stress conditions such as hypoxia. In addition to migratory and invasive capabilities, induction of EMT showed the ability to generate cells that exhibit molecular and functional stem-like characteristics, leading to the expression of stem-cell markers such as the CD44+/CD24−/low antigenic phenotype combined to the expression of ALDH-1. According to this hypothesis, tumors can originate from the transformation of normal adult tissue stem cells or from more differentiated progenitors that have acquired stem-like capabilities [42]. On the other hand, disseminated cancer cells can perform a mesenchymal-epithelial transition reverting to an epithelial phenotype in order to adhere and proliferate at distal sites [43].

This clonal heterogeneity confers greater resistance to selective environmental pressures and mostly to chemotherapy and radiation therapy [44]. As a matter of fact, high-grade tumors, typically the basal-like and triple-negative subtypes, showed the highest levels of genetic diversity and the highest number of cells that express molecular signatures characteristic of EMT, and thus they are associated with worse clinical outcomes [45]. On this basis, CSCs may represent an attractive and promising target for the development of future drugs. In particular, novel therapeutic options are directed to inhibit the pathways regulating the growth, survival, and self-renewal of CSCs, including the Notch, Wnt/β-catenin, Hh, and PI3K pathways (Figure 2) [46].

Akt represents a central hub in the Wnt/β-catenin and PI3K signaling pathways. Pharmacological inhibition of Akt may reduce tumor growth and regulate malignant stem cells [47]. Notch signaling is an evolutionarily conserved pathway that mediates communication between adjacent cells and plays both oncogenic and tumor-suppressor roles in various malignancies. Gammasecretes inhibitors represent an attractive therapeutic option for the inhibition of the Notch pathway and are currently under investigation in clinical trials for Alzheimer’s disease, T-cell acute lymphoblastic leukemia, and BC [46]. Furthermore, Harrison and colleagues [48] observed that Notch4 signaling activity was notably higher than Notch1 signaling activity in stem cell-enriched cell populations, suggesting that selective inhibition of Notch4 could be more effective and potentially less toxic.

Finally, several cytokines have been shown to be involved in the maintenance of CSCs, including interleukin (IL)-6 and IL-8. In particular, CXCR1/2, the receptor of IL-8, has been found to be overexpressed in cancer cells expressing the stem cell marker ALDH [49]. The interaction between CXCR1/2 and IL-8 increases CSC self-renewal; thus, CXCR1/2 blockade may represent another attractive target. Moreover, Singh and colleagues [50] recently observed an interaction between the CXCR1/2 signaling and the HER2 pathway, suggesting that HER2-blocking agents might synergize with CXCR1/2 inhibitors in targeting the CSCs. The clinical
evaluation and incorporation of stem-cell targeted therapies in the future management of patients with BC present challenges but also the opportunity to modify the natural history of the most aggressive forms of this disease.

**Immune pathway**

The immune system could play a role in the effectiveness of conventional anticancer treatments. Higher levels of tumor-infiltrating lymphocytes (TIL) have been associated with a higher rate of pCR after NACT, and post-chemotherapy TIL presence has been linked with better outcomes in patients who did not obtain pCR after neoadjuvant paclitaxel. Especially in TNBC, high levels of TIL in residual disease after NACT represent a strong prognostic factor and thus may help to identify patients who, despite residual disease, will have good outcome. Moreover, the conversion from originally low-TIL tumors into high-TIL tumors after NACT has been associated with a significant improvement in OS, suggesting that
chemotherapy could induce an antitumor immune response [51,52]. Also in the adjuvant setting, high TIL level has been significantly associated with decreased distant recurrence rates in primary TNBC treated with conventional adjuvant chemotherapy [53].

The involvement of the immune system has been confirmed even in trastuzumab antitumor activity. Recent evidence has demonstrated that TIL could predict efficacy of trastuzumab, since they increase its benefit in HER2-positive tumors [53]. These results suggest that immune infiltration may represent a useful parameter to stratify patients eligible for treatments, provide evidence for the development of immune-mediated therapies in BC, and may represent a surrogate for detection of NACT efficacy.

Conclusions

The use of advanced diagnostics in BC has increased our understanding of disease biology and is currently applied to clinical practice. Evaluation of standard biomarkers (ER, PR, and HER2) in primary BC can be supplemented by molecular profiling with significant information on disease subtyping, which constitutes prognostic and predictive data that can help in treatment planning. Moreover, the application of NGS and RPPA in the metastatic setting holds promise in further advancing precision medicine. Patients with a BC diagnosis can now benefit from selection of a number of novel targeted therapies that are either FDA-approved or under development and that have already translated to significant improvement in survival for this disease. Unfortunately, approximately 40,000 women a year still die of metastatic disease in the United States, suggesting that we have made limited strides in investigating and treating metastasis. The integration of CSC-targeted therapies and immune therapies in future combination regimens holds promise in addressing this unexplored area of clinical research and likely curing a larger proportion of women with metastatic BC.

Abbreviations

AR: Androgen receptor; BC: Breast cancer; BL: Basal-like; CDK: Cyclin-dependent kinase; CSC: Cancer stem cell; EGFR: Epidermal growth factor receptor; EMT: Epithelial-mesenchymal transition; ER: Estrogen receptor; EST1: Estrogen receptor 1; FDA: US Food and drug administration; FISH: Fluorescence in situ hybridization; HDAC: Histone deacetylase; HER2: Human epidermal growth factor receptor 2; IHC: Immunohistochemistry; IL: Interleukin; IRR: Immunoreactivity; LAR: Luminal androgen receptor; M: Mesenchymal; MSL: Mesenchymal stem-like; NACT: Neoadjuvant chemotherapy; NGS: Next-generation sequencing; OS: Overall survival; PAM50: Prediction analysis of microarray; PARP: Poly (ADP-ribose) polymerase; pCR: pathologic complete response; PFS: Progression-free survival; PR: Progesterone receptor; RB: Retinoblastoma tumor-suppressor protein; ROR: Risk of recurrence; RPPA: Reverse-phase protein microarray; RS: Recurrence score; TIL: Tumor-infiltrating lymphocytes; TNBC: Triple-negative breast cancer.

Competing interests

MC is a consultant for Dompé (Milan, Italy). AT declares that she has no competing interests.

Authors’ contributions

AT and MC contributed equally to the writing of the manuscript.

Author details

1Department of Oncology, Haematology and Respiratory Diseases, University of Modena and Reggio Emilia, Via del Pozzo 71, Modena 41125, Italy.
2Department of Medical Oncology, Jefferson University Hospital, 1100 Walnut Street, Philadelphia, PA 19107, USA.

Published online: 23 April 2015

References

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.
3. Sørlie T, Perou CM, Tibshirani R, Aas T, Geiser S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.
4. Nousek J, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678–85.
5. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271–7.
6. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–7.
7. Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol. 2011;9:48–57.
8. Gonzalves R, Bose R. Using multigene tests to select treatment for early-stage breast cancer. J Natl Compr Canc Netw. 2013;11:174–82.
9. Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickers T, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res. 2012;18:4465–72.
10. Filippis M, Nielsen TO, Rudas M, Greil R, Stöger H, Jääskeläinen R, et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with estrogen-responsive early breast cancer. Clin Cancer Res. 2014;20:1298–305.
11. Downsett M, Sestak I, Lopez-Knowles E, Siddiqui K, Dunbier AK, Cowens AW, et al. Comparison of PAM50 risk of recurrence score with oncotyping DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31:783–90.
12. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10:986.
13. Albain KS, Bang OW, Shek S, Hortobagyi GN, Livingston RB, Yeh JT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-negative, oestrogen-receptor-positive early breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55–65.
14. Krijgsman G, Roepman P, Zwart W, Carroll JS, Tian S, de Snoo FA, et al. Candidate luminal B breast cancer genes identified by genome, gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.
15. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTRNeoBC pooled analysis. Lancet. 2014;384:164–74.
16. Glück S, de Snoo F, Peeters J, Stork-Sloots L, Somo G. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013;139:759–67.
17. Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
18. Comen S, Gulle A, Aghajanian A, Addou-Klouche L, Finetti P, Saade MR, et al. Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling. PLoS One. 2014;9:e81843.
19. Fu X, Osborne CK, Schiff R. Biology and therapeutic potential of PI3K signaling in ER+HER2-negative breast cancer. Breast. 2013;22:Suppl 2:521–8.
20. Miller TW, Balko JM, Antea GL, Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29:452–61.
21. Baselga J, Campone M, Piccart M, Burris 3rd HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–9.

22. Thangavel C, Dean JL, Ertel A, Knudsen KE, Alldaz CM, Witkiewicz AK, et al. Therapeutically activating RB reestablishing cell cycle control in endocrine-therapy-resistant breast cancer. Endocr Relat Cancer. 2011;18:332–45.

23. Finn RS, Cowlip JR, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2014; Dec 15. pii: S1470-2045(14)71159-3. doi:10.1016/S1470-2045(14)71159-3. [Epub ahead of print].

24. Bojanga Jr P, Ramos KS. The promise and failures of epigenetic therapies for cancer treatment. Cancer Treat Rev. 2014;40:153–69.

25. Vesuna F, Lisk A, Kimble B, Domcek J, Kato Y, van der Groep P, et al. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α. Oncogene. 2012;31:3223–34.

26. Yardley DA, Islam-Khan RR, Melicher B, Lichtmaner M, Munster PN, Klein PM, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer. Breast Cancer Res. 2010;12:R68.

27. Tottora G, Mechanisms of resistance to HER2 target therapy. J Natl Cancer Inst Monogr. 2011;2011:95–8.

28. Olson E, Mullins D. When standard therapy fails in breast cancer: current and future options for HER2-positive disease. J Clin Trials. 2013;3:1000129.

29. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1781–93.

30. Baselga J, Verma S, Jungsi R, Huerde J, Guardino E, Fang L, et al. Relationship between tumor biomarkers (BM) and efficacy in ENNLA, a phase III study of trastuzumab emtansine (TDM1) in HER2-positive metastatic breast cancer (MBC) [abstract]. Cancer Res. 2013;3:Abstract nr LB-63.

31. Garcia-Carbonero R, Camero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 2013;14:e358–69.

32. Modi S, Strueck A, Linden H, Soott D, Chandralapaty S, Rosen N, et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tansyprin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res. 2011;17:132–9.

33. Jhaveri K, Chandralapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, et al. A phase ii open-label study of ganetespib, a novel heat shock protein 90 (HSP90) inhibitor for patients with metastatic breast cancer. Clin Breast Cancer. 2014;14:154–60.

34. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.

35. Guca P, Tolaney S, Isakoff SI, Ingle JN, Liu MC, Carey LA, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013;19:5505–12.

36. Pratt A, Parker JS, Karginova O, Fan C, Lisy C, Herrschkowitz JL, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68.

37. Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232:142–50.

38. Turner N, Moretti E, Siclari O, Migliaccio I, Santarpia L, D’Incalci M, et al. Targeting triple negative breast cancer: is p53 the answer? Cancer Treat Rev. 2013;39:541–50.

39. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23–8.

40. Ruesnes HG, Navin N, Hicks J, Borense-Dale AL. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest. 2011;121:3810–8.

41. May CD, Sphyris N, Evans KW, Werdin SJ, Guo W, Mani SA. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res. 2011;13:202.

42. Mani SA, Guo W, Liao M, Eaton EK, Attianan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15.